Sign in
Enrolling by invitationNo phase

Safety and Effectiveness Study of SQ-Kyrin TMVr System for Degenerated Mitral Regurgitation

Key facts

Who runs it
Shanghai Shenqi Medical Technology Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
118 people, planned
Started
15 Oct 2021
Expected to end
15 Dec 2028
Type of study
Interventional
Treatments tested
  • transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)
Record updated
20 June 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 38 criteriaShow less

Who can take part

  • Severe MR ≥3+ as determined by transthoracic echocardiography (TTE)
  • STS risk score results show that patients at high risk for traditional surgery or patients who cannot tolerate traditional thoracotomy: Subjects judged to be refractory to mitral valve surgery due to a ≥ 8% risk of death from STS surgery for surgical mitral valve replacement, or a ≥ 6% risk of death from STS surgery for surgical mitral valve repair, or because of any of the following risk factors:; Porcelain aorta or active ascending aortic plaque; Mediastinum treated with radiotherapy; Past mediastinitis; Left ventricular ejection fraction (LVEF) <40%; Presence of a patent coronary bypass implant; Acceptance of two or more cardiothoracic surgeries; Liver cirrhosis; Other surgical risk factors
  • Patients with Degenerated MR (Degenerated MR)
  • Age ≥ 18 years old, regardless of gender
  • Classification of cardiac function: NYHA class II, III or ambulatory class IV
  • Patients assessed by a multidisciplinary cardiac team as very high-risk or unsuitable for routine mitral valve surgery
  • Be able to understand the objective of the trial, and volunteered to participate and signed the Informed Consent Form, willing to accept the relevant examination and clinical follow-up
  • Left ventricular end-systolic diameter (LVESD)≤60mm
  • The MR beam mainly originates from the A2/P2 area
  • Mitral valve disease prolapse lesion area width≤15mm, prolapse height≤10mm, effective length of anterior and posterior valve leaflets>10mm
  • Mitral valve effective orifice area (EOA) ≥ 4.0cm2
  • No obvious calcification of mitral valve leaflets
  • Patient anatomy allows atrial septum approach

Who cannot take part

  • Patients who are extremely frail and cannot tolerate general anesthesia surgery or is in the state of shock requiring circulatory support
  • History of mitral valve surgery
  • Patients with infective endocarditis or suggestive of active infection
  • Complicated with severe untreated coronary artery disease
  • Patients with pulmonary hypertension (pulmonary systolic blood pressure>70mmHg)
  • Mitral regurgitation due to active rheumatic heart disease or rheumatic etiology
  • Patients with definite coagulation disorders and severe coagulation system diseases
  • Patients with stroke or transient cerebral ischemic attack within 30 days
  • Patients with other valve disease requiring surgery or interventional therapy
  • Patients with severe macrovascular disease requiring surgical treatment
  • Patients with inappropriate anatomical structures of the heart and valves indicated by imaging examinations
  • Known allergy to contrast agents and nickel-titanium memory alloy products
  • Patients with diseases that seriously affect the evaluation of treatment, such as patients with severe neurological lesions affecting cognitive ability, patients with malignant tumors, etc
  • Left ventricular ejection fraction <20%
  • Severe renal insufficiency (eGFR ≤ 25 mL/min) or requiring chronic renal replacement therapy
  • Patients with transthoracic echocardiographic evidence suggesting moderate-severe to severe right ventricular dysfunction
  • Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis
  • Patients with clear contraindications to the use of anticoagulants
  • Any intracardiac mass, left ventricular or atrial thrombus detected on transthoracic echocardiography
  • Severe tricuspid TR
  • Severe symptomatic carotid stenosis (>70% on ultrasonography) or carotid stenting within 30 days
  • R<testing systolic blood pressure 90 mmHg or >160 mmHg
  • Patient life expectancy < 12 months
  • Patients with severe thoracic deformity
  • Women who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To verify the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter produced by Shanghai Shenqi Medical Technology Co., Ltd.in patients with moderate-severe or severe degenerated mitral regurgitation (DMR).

The group in the trial

  • transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)Treatment being tested

    The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Single-Arm Clinical Trial to Assess the Safety and Efficacy of a Transcatheter Mitral Valve Clip Delivery System With Steerable Guide Catheter in Patients With Moderate-Severe or Severe Degenerative Mitral Regurgitation (DMR)
Publications
Record updated
20 June 2024